INmune Bio (INMB) Reports Key Findings from Phase 2 MINDFuL Trial of XPro

Go back to INmune Bio (INMB) Reports Key Findings from Phase 2 MINDFuL Trial of XPro
(NASDAQ: INMB) Delayed: 2.51 +0.07 (2.87%)
Previous Close $2.44    52 Week High
Open $2.44    52 Week Low
Day High $2.60    P/E N/A 
Day Low $2.41    EPS
Volume 494,310